GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Net Current Asset Value

Psyence Biomedical (Psyence Biomedical) Net Current Asset Value : $-0.02 (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Psyence Biomedical's net current asset value per share for the quarter that ended in Mar. 2023 was $-0.02.

The historical rank and industry rank for Psyence Biomedical's Net Current Asset Value or its related term are showing as below:

PBM's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.95
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Psyence Biomedical Net Current Asset Value Historical Data

The historical data trend for Psyence Biomedical's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Net Current Asset Value Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Net Current Asset Value
- 0.13 -0.02

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Net Current Asset Value - 0.13 -0.02

Competitive Comparison of Psyence Biomedical's Net Current Asset Value

For the Biotechnology subindustry, Psyence Biomedical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Price-to-Net-Current-Asset-Value falls into.



Psyence Biomedical Net Current Asset Value Calculation

Psyence Biomedical's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(A: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.573-1.771-0-0)/12.745
=-0.02

Psyence Biomedical's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.573-1.771-0-0)/12.745
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Biomedical  (NAS:PBM) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Psyence Biomedical Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines